Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

March 31, 2025

Conditions
Drug Interactions
Interventions
DRUG

Nintedanib 150 MG [Ofev]

Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

PureTech

INDUSTRY

NCT06717100 - Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib | Biotech Hunter | Biotech Hunter